Jazz Pharmaceuticals (JAZZ) is back in focus after first quarter results showed revenue of US$1,068.9 million and net income of US$293.1 million, with management reaffirming full year guidance and pointing to upcoming FDA and study milestones.

The stock has climbed steadily, with a 30 day share price return of 12.46% and a 90 day share price return of 37.56%. The 1 year total shareholder return of 109.92% highlights strong momentum around earnings and upcoming catalysts.

If strong execution in areas like sleep, epilepsy, and oncology is on your radar, it may be a good time to broaden your search and check out 32 healthcare AI stocks

After a quarter with US$1,068.9 million in revenue, a swing to US$293.1 million in net income, and a 1 year total shareholder return above 100%, the key question is simple: is Jazz still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 1% Overvalued

The most followed narrative pegs Jazz Pharmaceuticals' fair value at $225.53, slightly below the last close of $228.77, which puts every assumption under the microscope.

Analysts are assuming Jazz Pharmaceuticals's revenue will grow by 7.0% annually over the next 3 years.

Analysts assume that profit margins will increase from 8.3% loss today to 25.3% in 3 years time.

Want to see what backs this near full pricing call? The narrative leans on firm revenue expansion, a sharp margin reset, and a future earnings multiple that lines up with those forecasts.

Result: Fair Value of $225.53 (OVERVALUED)

However, there are clear pressure points to watch, including potential generic competition for oxybate products and execution risk related to key oncology trial readouts and launches.

Another Angle on Value

The community narrative frames Jazz Pharmaceuticals as roughly 1% overvalued around $225.53, yet the market is assigning a very different signal on sales. At a P/S of 3.2x, the stock sits well below the US Pharmaceuticals average of 5.5x and below its own fair ratio of 7.6x, even though it trades above a 2x peer average. That gap suggests investors either see meaningful risk in the story or have not fully repriced recent developments. Which side do you think has it right?

Next Steps

Mixed signals in the story so far? With both risks and rewards on the table, it pays to move quickly and weigh the 2 key rewards and 4 important warning signs

Looking for more investment ideas?

If Jazz is already on your radar, do not stop there. Broaden your watchlist with fresh ideas that match your style before the next opportunity moves on.

• Target dependable compounding potential by screening for companies trading below their estimated worth using the 51 high quality undervalued stocks.
• Focus on income strength by reviewing companies offering higher yields through the 13 dividend fortresses.
• Prioritize resilience by checking out companies highlighted in the 65 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.